1. Staessen JA, Wang J, Bianchi G, Birkenhager WH. Essential hypertension. Lancet 2003;361:1629–1641.
3. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation 2018;138:e426–e483.
4. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 2018;36:1953–2041.
6. Blood Pressure Lowering Treatment Trialists’ Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet 2021;397:1625–1636.
8. Itoga NK, Tawfik DS, Montez-Rath ME, Chang TI. Contributions of systolic and diastolic blood pressures to cardiovascular outcomes in the ALLHAT Study. J Am Coll Cardiol 2021;78:1671–1678.
9. Pareek M, Vaduganathan M, Biering-Sorensen T, et al. Pulse pressure, cardiovascular events, and intensive blood-pressure lowering in the systolic blood pressure intervention trial (SPRINT). Am J Med 2019;132:733–739.
11. Lee TC, Cavalcanti RB, McDonald EG, Pilote L, Brophy JM. Diastolic hypotension may attenuate benefits from intensive systolic targets: secondary analysis of a randomized controlled trial. Am J Med 2018;131:1228–1233.
18. SCORE2 Working Group and ESC Cardiovascular Risk Collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 2021;42:2439–2454.
19. Lawes CM, Rodgers A, Bennett DA, et al. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003;21:707–716.
22. Kromhout D. Epidemiology of cardiovascular diseases in Europe. Public Health Nutr 2001;4(2B):441–457.
25. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;363:2049–2051.
27. SPRINT Research Group; Lewis CE, et al.; Fine LJ. Final report of a trial of intensive versus standard blood-pressure control. N Engl J Med 2021;384:1921–1930.
29. Burgess SE, MacLaughlin EJ, Smith PA, Salcido A, Benton TJ. Blood pressure rising: differences between current clinical and recommended measurement techniques. J Am Soc Hypertens 2011;5:484–488.
32. Lim NK, Park HY, Kim WH, Mancia G, Cho MC. The U-shaped association between achieved blood pressure and risk of cardiovascular events and mortality in elderly and younger patients. J Hypertens 2020;38:1559–1566.
33. Bohm M, Schumacher H, Teo KK, et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet 2017;389:2226–2237.
35. Messerli FH, Shalaeva EV, Rexhaj E. Optimal BP targets to prevent stroke and MI: is there a lesser of 2 evils? J Am Coll Cardiol 2021;78:1679–1681.
37. Kowalski C, Yang K, Charron T, et al. Inaccuracy of brachial blood pressure and its potential impact on treatment and aortic blood pressure estimation. J Hypertens 2021;39:2370–2378.
38. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543–551.